Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial

The Lancet Oncology

Volumn 17, Issue 9, 2016, Pages 1272-1282

  Brose, Marcia S ^a   Cabanillas, Maria E ^b   Cohen, Ezra E W ^c   Wirth, Lori J ^d   Riehl, Todd ^e   Yue, Huibin ^e   Sherman, Steven I ^b   Sherman, Eric J ^f  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e GENENTECH INC   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; B RAF KINASE; GAMMA GLUTAMYLTRANSFERASE; RADIOACTIVE IODINE; URIC ACID; VEMURAFENIB; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; INDOLE DERIVATIVE; SULFONAMIDE; TUMOR MARKER;

ACTINIC KERATOSIS; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; ANAL HAEMORRHAGE; ANEMIA; ANGINA PECTORIS; ANUS DISEASE; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; ATRIAL FIBRILLATION; BACKACHE; BASAL CELL CARCINOMA; BRAF GENE; CARDIOMEGALY; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; CONJUNCTIVITIS; CONSTIPATION; CONVULSION; COUGHING; DARIER DISEASE; DECREASED APPETITE; DEHYDRATION; DERMATITIS; DIARRHEA; DISEASE SEVERITY; DIVERTICULITIS; DIZZINESS; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; DYSGEUSIA; DYSPHAGIA; DYSPNEA; EPIDERMOID CYST; ESOPHAGUS HEMORRHAGE; FATIGUE; FEMALE; FEVER; FIBROMA; FOOD POISONING; GAIT DISORDER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENE MUTATION; HAND FOOT SYNDROME; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEADACHE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERKERATOSIS; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPERURICEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; INSOMNIA; INTENTION TO TREAT ANALYSIS; KERATOACANTHOMA; LARGE INTESTINE PERFORATION; LARYNGITIS; LARYNX EDEMA; LEUKOCYTE COUNT; LICHEN PLANUS; LIMB PAIN; LIVER TOXICITY; LUNG HEMORRHAGE; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALAISE; MALE; MEDIAN SURVIVAL TIME; MELANOMA; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; NECK PAIN; OVERALL SURVIVAL; PARESTHESIA; PATHOLOGIC FRACTURE; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PHOTOSENSITIVITY; PIGMENTED NEVUS; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; PRURITUS; QT PROLONGATION; RASH; SKIN CARCINOMA; SKIN DEFECT; SKIN INDURATION; SKIN PAPILLOMA; STOMACH ADENOCARCINOMA; THORAX PAIN; THYROID CANCER; TRACHEA CARCINOMA; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; URIC ACID BLOOD LEVEL; URINARY TRACT INFECTION; VOMITING; CANCER STAGING; CARCINOMA, PAPILLARY; CLINICAL TRIAL; DRUG EFFECTS; ENZYME IMMUNOASSAY; FOLLOW UP; GENETICS; LYMPH NODE METASTASIS; MIDDLE AGED; MUTATION; PATHOLOGY; PROGNOSIS; RADIATION TOLERANCE; SALVAGE THERAPY; SECONDARY; SURVIVAL RATE; THYROID NEOPLASMS;

AGED; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CARCINOMA, PAPILLARY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; INDOLES; IODINE RADIOISOTOPES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; RADIATION TOLERANCE; SALVAGE THERAPY; SULFONAMIDES; SURVIVAL RATE; THYROID NEOPLASMS;

EID: 84994525204     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(16)30166-8     Document Type: Article

References (25)

1. 1 Ferlay, J, Soerjomataram, I, Dikshit, R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136 (2015), E359–E386.
2. 2 Siegel, RL, Miller, KD, Jemal, A, Cancer statistics, 2015. CA Cancer J Clin 65 (2015), 5–29.
3. 3 Hodak, SP, Carty, SE, Radioiodine-resistant differentiated thyroid cancer: hope for the future. Oncology 23 (2009), 775–776.
4. 4 Durante, C, Haddy, N, Baudin, E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 91 (2006), 2892–2899.
5. 5 Mehra, R, Cohen, RB, New agents in the treatment for malignancies of the salivary and thyroid glands. Hematol Oncol Clin North Am 22 (2008), 1279–1295.
6. 6 Sherman, SI, Wirth, LJ, Droz, JP, et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 359 (2008), 31–42.
7. 7 Bible, KC, Suman, VJ, Molina, JR, et al. for the Endocrine Malignancies Disease Oriented Group Mayo Clinic Cancer Center, the Mayo Phase 2 Consortium. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol 11 (2010), 962–972.
8. 8 Cabanillas, ME, Schlumberger, M, Jarzab, B, et al. A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: a clinical outcomes and biomarker assessment. Cancer 121 (2015), 2749–2756.
9. 9 Cabanillas, ME, Brose, MS, Ramies, DA, Lee, Y, Miles, D, Sherman, SI, Antitumor activity of cabozantinib (XL184) in a cohort of patients (pts) with differentiated thyroid cancer (DTC). Proc Am Soc Clin Oncol, 30, 2012 abstr 5547.
10. 10 Cohen, EE, Rosen, LS, Vokes, EE, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 26 (2008), 4708–4713.
11. 11 Leboulleux, S, Bastholt, L, Krause, T, et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol 13 (2012), 897–905.
12. 12 Brose, MS, Nutting, CM, Jarzab, B, et al., on behalf of the DECISION investigators. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 384 (2014), 319–328.
13. 13 Schlumberger, M, Tahara, M, Wirth, LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 372 (2015), 621–630.
14. 14 Xing, M, BRAF mutation in thyroid cancer. Endocr Relat Cancer 12 (2005), 245–262.
15. 15 Fallahi, P, Ferrari, SM, Santini, F, et al. Sorafenib and thyroid cancer. BioDrugs 27 (2013), 615–628.
16. 16 Elisei, R, Ugolini, C, Viola, D, et al. BRAF (V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab 93 (2008), 3943–3955.
17. 17 Xing, M, Westra, WH, Tufano, RP, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 90 (2005), 6373–6379.
18. 18 Xing, M, Alzahrani, AS, Carson, KA, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA 309 (2013), 1493–1501.
19. 19 Chapman, PB, Hauschild, A, Robert, C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364 (2011), 2507–2516.
20. 20 Kim, KB, Cabanillas, ME, Lazar, AJ, et al. Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation. Thyroid 23 (2013), 1277–1283.
21. 21 Dadu, R, Shah, K, Busaidy, NL, et al. Efficacy and tolerability of vemurafenib in patients with BRAF(V600E)-positive papillary thyroid cancer: MD Anderson Cancer Center off label experience. J Clin Endocrinol Metab 100 (2015), E77–E81.
22. 22 Powell, N, Jeremiah, S, Morishita, M, et al. Frequency of BRAF T1796A mutation in papillary thyroid carcinoma relates to age of patient at diagnosis and not to radiation exposure. J Pathol 205 (2005), 558–564.
23. 23 Adeniran, AJ, Zhu, Z, Gandhi, M, et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol 30 (2006), 216–222.
24. 24 Flaherty, KT, Puzanov, I, Kim, KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363 (2010), 809–819.
25. 25 Su, F, Viros, A, Milagre, C, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 366 (2012), 207–215.